CMPX · Why this verdict
Why Compass Therapeutics (CMPX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine flagged the raw analyst target of $8.50 as implausible against a $2.27 price (a 3.7x ratio) and rejected it, falling back to a technical resistance-based target of just $2.24, which erases modeled upside to -1.3%. Bear case | If this data-quality concern persists, expect the technical target to remain the operative price target with little to no modeled upside over the next 12 months. | →Stable |
| CounterEven with the raw target rejected, the underlying sentiment score of 8.0 and an analyst upside read of 274% suggest covering analysts still see substantial fundamental upside that the technical target does not capture. | ||
The stock shows a death-cross recovery setup with MACD improving and RSI at 70, but the momentum notes label this an overbought bear-market rally and confirm the underlying trend remains below the 200-day moving average with a -3.6% per 30-day slope. Momentum breakdown | For the recovery to be genuine, momentum should keep rising past the current 5.7 without reverting, and price should reclaim the 200-day moving average within 12 months. | →Stable |
| CounterLabeling the move a bear rally implies the bounce could be short-covering rather than a durable reversal of the confirmed downtrend. | ||
Quality reads a severe 1.2 versus the 4.0 floor, driven by cash-burning operations, no competitive moat, and a weak Piotroski F-score of 2 out of 9. Quality breakdown | Quality should rise materially above the 4.0 floor as cash burn slows and the Piotroski score improves over the next 12 months. | →Stable |
| CounterA current ratio of 5 suggests the company retains meaningful near-term liquidity despite the weak quality profile, buying time before quality concerns become a solvency issue. | ||
The engine finds asymmetry exhausted with 0% modeled upside and no clear trading edge, keeping this highly speculative, binary-outcome biotech position at avoid-level sizing with zero conviction. Gates warning | If this remains true, expect the position-size recommendation to stay at avoid and conviction to stay at none over the next 12 months absent a new catalyst. | →Stable |
| CounterOptions-market max pain sits at $9.00, nearly four times the current price, suggesting options participants may be pricing a much larger potential move than the engine's exhausted-upside read implies. | ||
Short interest is elevated at 22%, flagged by the risk notes as justified, adding a distinct risk dimension beyond the quality and valuation concerns already identified. Key risks | If the thesis holds, short interest should remain elevated near current levels or rise further as the underlying downtrend persists over the next 12 months. | →Stable |
| CounterHigh short interest paired with an emerging recovery setup can fuel a short squeeze, which would push the price higher independent of any fundamental improvement. | ||
The engine flagged the raw analyst target of $8.50 as implausible against a $2.27 price (a 3.7x ratio) and rejected it, falling back to a technical resistance-based target of just $2.24, which erases modeled upside to -1.3%.
→StableBear case
- Expectation
- If this data-quality concern persists, expect the technical target to remain the operative price target with little to no modeled upside over the next 12 months.
CounterEven with the raw target rejected, the underlying sentiment score of 8.0 and an analyst upside read of 274% suggest covering analysts still see substantial fundamental upside that the technical target does not capture.
The stock shows a death-cross recovery setup with MACD improving and RSI at 70, but the momentum notes label this an overbought bear-market rally and confirm the underlying trend remains below the 200-day moving average with a -3.6% per 30-day slope.
→StableMomentum breakdown
- Expectation
- For the recovery to be genuine, momentum should keep rising past the current 5.7 without reverting, and price should reclaim the 200-day moving average within 12 months.
CounterLabeling the move a bear rally implies the bounce could be short-covering rather than a durable reversal of the confirmed downtrend.
Quality reads a severe 1.2 versus the 4.0 floor, driven by cash-burning operations, no competitive moat, and a weak Piotroski F-score of 2 out of 9.
→StableQuality breakdown
- Expectation
- Quality should rise materially above the 4.0 floor as cash burn slows and the Piotroski score improves over the next 12 months.
CounterA current ratio of 5 suggests the company retains meaningful near-term liquidity despite the weak quality profile, buying time before quality concerns become a solvency issue.
The engine finds asymmetry exhausted with 0% modeled upside and no clear trading edge, keeping this highly speculative, binary-outcome biotech position at avoid-level sizing with zero conviction.
→StableGates warning
- Expectation
- If this remains true, expect the position-size recommendation to stay at avoid and conviction to stay at none over the next 12 months absent a new catalyst.
CounterOptions-market max pain sits at $9.00, nearly four times the current price, suggesting options participants may be pricing a much larger potential move than the engine's exhausted-upside read implies.
Short interest is elevated at 22%, flagged by the risk notes as justified, adding a distinct risk dimension beyond the quality and valuation concerns already identified.
→StableKey risks
- Expectation
- If the thesis holds, short interest should remain elevated near current levels or rise further as the underlying downtrend persists over the next 12 months.
CounterHigh short interest paired with an emerging recovery setup can fuel a short squeeze, which would push the price higher independent of any fundamental improvement.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Compass Therapeutics' headline analyst upside rests on a price target the engine itself rejected as implausible, and while the stock shows an overbought bounce off a death cross, deep quality problems, cash burn, and elevated short interest keep conviction and position sizing at essentially zero.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 3.2 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 7.2 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 1.5 |
- ▸Overbought bear rally (RSI 70)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -3.6%/30d — confirmed downtrend
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.4 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 271%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 3.3 |
| growth rank | 5.0 |
Technical
0.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.2 |
| 52w position | 0.0 |
Risk (lower is worse)
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 2.6 |
| volatility | 1.2 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 8.5 |
| debt equity | 0.0 |
- ▸High short interest justified: 22%
- ▸Elevated put/call: 2.00
- ▸High IV: 134%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 5.4 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:5.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:39d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- DEATH_CROSS:momentum=5.5>=5.0 recovering
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 70
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -67% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 8.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 8.0, Momentum at 5.5, and Value at 5.0; the weakest are Technical at 0.1, Quality at 1.2, and Risk (lower is worse) at 2.6. The V9 engine cleared all gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Rejected Analyst Target Caps Upside
Trip ifModeled upside rises above 20% as a revalidated price target replaces the current technical target of $2.24.
- P2Death Cross Recovery As Overbought Bounce
Trip ifMomentum score falls below 5.0, confirming the bounce was a bear-market rally rather than a genuine recovery.
- P3Quality Deficit From Cash Burn
Trip ifQuality score rises above 4.0 from the current 1.2.
- P4Upside Exhausted With No Clear Edge
Trip ifModeled upside rises above 15% as the engine identifies a clear trading edge, replacing the current 0% exhausted reading.
- P5Elevated Short Interest Risk
Trip ifShort interest falls below 10% of float, down from the current 22%.